NASHVILLE, Tenn., June 22, 2021 /PRNewswire/ -- Cryoport, Inc.
(NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in
temperature-controlled supply chain solutions for the life sciences
industry, today announced that Cellenkos®, Inc.,
a privately held, clinical-stage biotechnology company, has
selected Cryoport to provide a staged, on-demand, logistics
solution for COVID-19 therapy shipments for patients in need.
Working in concert, Cryoport Systems, CRYOPDP and CRYOGENE will
provide the highest possible available level of tracking and
proactive management for the therapies, including continuous
monitoring of each step from scheduling, collection, confirming
courier pickups/deliveries, and monitoring transport. Under the
terms of the agreement, Cryoport Systems delivers its Cryoport
Express® Shippers to Cellenkos' manufacturing facility
in Houston, Texas, on a weekly
basis. When a patient is identified, the team at Cellenkos
places their therapy inside the shipper and notifies Cryoport
Systems. The Cryoport Express® Shipper is collected and
delivered to the patient the same day or the next day for longer
journeys. During the entire process, Cellenkos®
has full visibility and oversight through the cloud based
Cryoportal® Logistics Management Platform which provides
near real-time tracking and monitoring of the shipment and the
SmartPak II® Condition Monitoring System, supported by
the Cryoport Systems' 24/7 customer support team. Furthermore,
CRYOPDP provides some of the logistics support and CRYOGENE
provides biostorage services for Cellenkos at its nearby
state-of-the-art facility.
"Having three of our Cryoport companies provide flexible
logistics support for the various stages of Cellenkos' COVID-19
therapy shipments demonstrates our ongoing commitment to helping
clients find the best possible solutions for patients who need to
be treated quickly and is a clear demonstration of the value of our
integrated supply chain platform," said Jerrell Shelton, CEO, Cryoport. "We look forward
to working closely with Cellenkos to support the company with our
full range of temperature-controlled solutions to help patients
suffering from COVID-19 recover and return to their daily
lives."
"Cryoport's best-in-class solutions enable Cellenkos to rapidly
respond to patients' urgent needs, without needing advanced notice
and providing full visibility while treatments are in transit,"
added Tara Sadeghi, Vice President,
Clinical Operations, Cellenkos®. "Temperature-controlled
logistics solutions are vital for our therapy's success, and with
the flexibility provided by Cryoport Systems, CRYOGENE and CRYOPDP,
we are able to have consistent, reliable support at each stage of
our therapy's journey to the patient. During the pandemic,
Cryoport's seamless and dependable delivery logistics allowed for
Cellenkos to treat critically sick, intubated patients suffering
from COVID-19 ARDS with a narrow therapeutic window in multi-center
clinical study (Phase 1 Double-Blinded, Randomized, Placebo
Controlled Safety and Early Efficacy Trial of Cryopreserved Cord
Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment
Of COVID-19 Induced Acute Respiratory Distress Syndrome ("ARDS")
NCT04468971).
"Our confidence in Cryoport's outstanding ability to solve for a
major point of failure in the cell therapeutics is exemplified by
our alliance with them to be our logistics partner for the
multi-center, randomized placebo control trial of CK0802 for
treatment of COVID-19 ARDS: RESOLVE Trial (Regulatory T cell
infusion for lung injury due to COVID-19, NCT04468971) as well as
for our future planned studies."
About Cryoport, Inc.
Cryoport, Inc. (NASDAQ: CYRX) is
redefining temperature-controlled supply chain support for the life
sciences industry by continually broadening its platform of
solutions and services, serving the Biopharma, Animal Health, and
Reproductive Medicine markets. Through its family of companies,
Cryoport Systems, MVE Biological Solutions, CRYOPDP and CRYOGENE,
Cryoport provides strategic solutions that support the growing
needs of these markets.
Cryoport's mission is to support life and health on earth
through its advanced technologies, global supply chain network and
dedicated scientists, technicians and supporting teams of
professionals. Cryoport serves clients in life sciences research,
clinical trials, and product commercialization. We support the
creation of life, the sustaining of life and life-saving advanced
cell and gene therapies in over 100 countries around the world. For
more information, visit www.cryoport.com or follow @cryoport on
Twitter at www.twitter.com/cryoport for live updates.
About Cellenkos®, Inc.
Cellenkos® is a clinical-stage biotechnology company
focused on development and commercialization of Allogeneic,
Tissue-Targeted, Immune T-Regulatory Cell Therapies to Treat
Autoimmune Diseases and Inflammatory Disorders. Being derived from
umbilical cord blood (CB), Cellenkos' T-Regulatory cells (Tregs)
are naïve, bonafide suppressor cells that resolve inflammation
through multiple direct and indirect interactions. Cellenkos
utilizes its' proprietary CRANETM platform technology to isolate,
activate, enrich and expand the tissue directed CB Treg cells that
leverage cellular intelligence to seek, localize, proliferate and
resolve tissue inflammation. Cellenkos' in-house cGMP facility
allows for large scale manufacturing where multiple doses can be
generated from single cord blood unit. These off-the-shelf
allogeneic cell products are cryopreserved and are available
on-demand for infusion at the point-of-care.
Currently, Cellenkos® has completed enrollment for: i) Phase I
trial of CK0801 in patients with Bone Marrow Failure Syndrome
(NCT03773393), and ii) Phase 1 Double-Blinded, Randomized, Placebo
Controlled Safety and Early Efficacy Trial of CK0802 in the
Treatment of COVID-19 Induced ARDS (NCT04468971). Cellenkos® is in
process for IND submission for i) Phase 1b, open-label study of add on therapy with
CK0804 in participants with myelofibrosis, with suboptimal response
to ruxolitinib, and ii) Phase I trial of CK0803 for the treatment
of Amyotrophic Lateral Sclerosis.
For more information, please visit www.cellenkosinc.com.
Forward-Looking Statements
Statements in
this press release which are not purely historical, including
statements regarding the Company's intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future, are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, those
related to the Company's industry, business, plans, strategy,
acquisitions, including CRYOPDP and MVE Biological Solutions,
financial results and financial condition. It is important to
note that the Company's actual results could differ materially from
those in any such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not
limited to, risks and uncertainties associated with the effect of
changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
discussed in the Company's Securities and Exchange Commission
("SEC") reports including, but not limited to, the Company's Annual
Report on Form 10-K for the three and twelve months ended
December 31, 2020 and any subsequent
filings with the SEC. The forward-looking statements contained in
this press release speak only as of the date hereof and the Company
cautions investors not to place undue reliance on these
forward-looking statements. Except as required by law, the Company
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cellenkos-selects-cryoport-to-support-on-demand-flexible-covid-19-therapy-shipments-to-patients-in-need-301317091.html
SOURCE Cryoport, Inc.